Bank Of America Corp Spero Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 5,654 shares of SPRO stock, worth $6,671. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,654

Previous 5,558 1.73%

Holding current value

$6,671

Previous $7,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.19 - $1.5 $114 - $144	96 Added 1.73%	5,654 $7,000
Q2 2024 Aug 14, 2024	BUY	$1.27 - $1.8 $464 - $658	366 Added 7.05%	5,558 $7,000
Q1 2024 May 15, 2024	SELL	$1.35 - $1.79 $753 - $998	-558 Reduced 9.7%	5,192 $8,000
Q4 2023 Feb 14, 2024	SELL	$1.0 - $1.47 $7,487 - $11,005	-7,487 Reduced 56.56%	5,750 $8,000
Q2 2023 Aug 14, 2023	SELL	$1.42 - $1.95 $7,355 - $10,101	-5,180 Reduced 28.13%	13,237 $19,000
Q1 2023 May 12, 2023	BUY	$1.35 - $2.0 $14,146 - $20,958	10,479 Added 132.01%	18,417 $26,000
Q4 2022 Feb 10, 2023	SELL	$1.55 - $2.12 $2,856 - $3,907	-1,843 Reduced 18.84%	7,938 $13,000
Q3 2022 Nov 14, 2022	SELL	$0.68 - $2.2 $5,979 - $19,346	-8,794 Reduced 47.34%	9,781 $19,000
Q2 2022 Aug 12, 2022	BUY	$0.74 - $7.44 $6,486 - $65,211	8,765 Added 89.35%	18,575 $13,000
Q1 2022 May 16, 2022	SELL	$7.87 - $15.15 $250,604 - $482,421	-31,843 Reduced 76.45%	9,810 $85,000
Q4 2021 Feb 08, 2022	BUY	$13.09 - $18.77 $366,323 - $525,278	27,985 Added 204.75%	41,653 $667,000
Q3 2021 Nov 15, 2021	BUY	$13.03 - $19.51 $77,750 - $116,416	5,967 Added 77.48%	13,668 $251,000
Q2 2021 Sep 13, 2021	BUY	$12.22 - $15.79 $94,106 - $121,598	7,701 New	7,701 $107,000

Others Institutions Holding SPRO

# of Institutions

Shares Held

13.9M

Call Options Held

200

Put Options Held

200

View Full List

About Spero Therapeutics, Inc.

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $41.4M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

More about SPRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Spero Therapeutics, Inc. Transaction History